Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 330

1.

Comparison of Radiographic Approaches to Assess Treatment Response in Pituitary Adenomas: Is RECIST or RANO Good Enough?

Imber BS, Lin AL, Zhang Z, Keshavamurthy KN, Deipolyi AR, Beal K, Cohen MA, Tabar V, DeAngelis LM, Geer EB, Yang TJ, Young RJ.

J Endocr Soc. 2019 Jul 2;3(9):1693-1706. doi: 10.1210/js.2019-00130. eCollection 2019 Sep 1.

2.

Cancer-Related Ischemic Stroke Has a Distinct Blood mRNA Expression Profile.

Navi BB, Mathias R, Sherman CP, Wolfe J, Kamel H, Tagawa ST, Saxena A, Ocean AJ, Iadecola C, DeAngelis LM, Elkind MSV, Hull H, Jickling GC, Sharp FR, Ander BP, Stamova B.

Stroke. 2019 Sep 12:STROKEAHA119026143. doi: 10.1161/STROKEAHA.119.026143. [Epub ahead of print]

PMID:
31510897
3.

Frequency and outcomes of brain metastases in patients with HER2-mutant lung cancers.

Offin M, Feldman D, Ni A, Myers ML, Lai WV, Pentsova E, Boire A, Daras M, Jordan EJ, Solit DB, Arcila ME, Jones DR, Isbell JM, Beal K, Young RJ, Rudin CM, Riely GJ, Drilon A, Tabar V, DeAngelis LM, Yu HA, Kris MG, Li BT.

Cancer. 2019 Aug 30. doi: 10.1002/cncr.32461. [Epub ahead of print]

PMID:
31469421
4.

Longitudinal cognitive assessment in patients with primary CNS lymphoma treated with induction chemotherapy followed by reduced-dose whole-brain radiotherapy or autologous stem cell transplantation.

Correa DD, Braun E, Kryza-Lacombe M, Ho KW, Reiner AS, Panageas KS, Yahalom J, Sauter CS, Abrey LE, DeAngelis LM, Omuro A.

J Neurooncol. 2019 Sep;144(3):553-562. doi: 10.1007/s11060-019-03257-1. Epub 2019 Aug 3.

PMID:
31377920
5.

Phase II trial of an AKT inhibitor (perifosine) for recurrent glioblastoma.

Kaley TJ, Panageas KS, Mellinghoff IK, Nolan C, Gavrilovic IT, DeAngelis LM, Abrey LE, Holland EC, Lassman AB.

J Neurooncol. 2019 Sep;144(2):403-407. doi: 10.1007/s11060-019-03243-7. Epub 2019 Jul 19.

PMID:
31325145
6.

Genomic Correlates of Disease Progression and Treatment Response in Prospectively Characterized Gliomas.

Jonsson P, Lin AL, Young RJ, DiStefano NM, Hyman DM, Li BT, Berger MF, Zehir A, Ladanyi M, Solit DB, Arnold AG, Stadler ZK, Mandelker D, Goldberg ME, Chmielecki J, Pourmaleki M, Ogilvie SQ, Chavan SS, McKeown AT, Manne M, Hyde A, Beal K, Yang TJ, Nolan CP, Pentsova E, Omuro A, Gavrilovic IT, Kaley TJ, Diamond EL, Stone JB, Grommes C, Boire A, Daras M, Piotrowski AF, Miller AM, Gutin PH, Chan TA, Tabar VS, Brennan CW, Rosenblum M, DeAngelis LM, Mellinghoff IK, Taylor BS.

Clin Cancer Res. 2019 Sep 15;25(18):5537-5547. doi: 10.1158/1078-0432.CCR-19-0032. Epub 2019 Jul 1.

PMID:
31263031
7.

Letter: When Less is More: Dexamethasone Dosing for Brain Tumors.

Lim-Fat MJ, Bi WL, Lo J, Lee EQ, Ahluwalia MS, Batchelor TT, Chang SM, Chiocca EA, Chukwueke U, Cloughesy TF, Colman H, Deangelis LM, Galanis E, Gilbert MR, De Groot JF, Lassman AB, Liau LM, Mason W, McFaline-Figueroa JR, Mehta MP, Mellinghoff IK, Nabors LB, Nayak L, Reardon DA, Wen PY.

Neurosurgery. 2019 Sep 1;85(3):E607-E608. doi: 10.1093/neuros/nyz186. No abstract available.

PMID:
31215634
8.

The immunopathogenesis of oral lichen planus-Is there a role for mucosal associated invariant T cells?

DeAngelis LM, Cirillo N, McCullough MJ.

J Oral Pathol Med. 2019 Aug;48(7):552-559. doi: 10.1111/jop.12898. Epub 2019 Jun 21.

PMID:
31172572
9.

Genetic variants and cognitive functions in patients with brain tumors.

Correa DD, Satagopan J, Martin A, Braun E, Kryza-Lacombe M, Cheung K, Sharma A, Dimitriadoy S, O'Connell K, Leong S, Karimi S, Lyo J, DeAngelis LM, Orlow I.

Neuro Oncol. 2019 Oct 9;21(10):1297-1309. doi: 10.1093/neuonc/noz094.

PMID:
31123752
10.

Electrophysiological findings in immune checkpoint inhibitor-related peripheral neuropathy.

Chen X, Haggiagi A, Tzatha E, DeAngelis LM, Santomasso B.

Clin Neurophysiol. 2019 Aug;130(8):1440-1445. doi: 10.1016/j.clinph.2019.03.035. Epub 2019 May 9.

PMID:
31103410
11.

Leptomeningeal metastases in glioma: The Memorial Sloan Kettering Cancer Center experience.

Andersen BM, Miranda C, Hatzoglou V, DeAngelis LM, Miller AM.

Neurology. 2019 May 21;92(21):e2483-e2491. doi: 10.1212/WNL.0000000000007529. Epub 2019 Apr 24.

PMID:
31019097
12.

Global consequences of malignant CNS tumours: a call to action.

DeAngelis LM.

Lancet Neurol. 2019 Apr;18(4):324-325. doi: 10.1016/S1474-4422(19)30083-3. Epub 2019 Feb 21. No abstract available.

13.

Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial.

Wen PY, Touat M, Alexander BM, Mellinghoff IK, Ramkissoon S, McCluskey CS, Pelton K, Haidar S, Basu SS, Gaffey SC, Brown LE, Martinez-Ledesma JE, Wu S, Kim J, Wei W, Park MA, Huse JT, Kuhn JG, Rinne ML, Colman H, Agar NYR, Omuro AM, DeAngelis LM, Gilbert MR, de Groot JF, Cloughesy TF, Chi AS, Roberts TM, Zhao JJ, Lee EQ, Nayak L, Heath JR, Horky LL, Batchelor TT, Beroukhim R, Chang SM, Ligon AH, Dunn IF, Koul D, Young GS, Prados MD, Reardon DA, Yung WKA, Ligon KL.

J Clin Oncol. 2019 Mar 20;37(9):741-750. doi: 10.1200/JCO.18.01207. Epub 2019 Feb 4.

14.

Tracking tumour evolution in glioma through liquid biopsies of cerebrospinal fluid.

Miller AM, Shah RH, Pentsova EI, Pourmaleki M, Briggs S, Distefano N, Zheng Y, Skakodub A, Mehta SA, Campos C, Hsieh WY, Selcuklu SD, Ling L, Meng F, Jing X, Samoila A, Bale TA, Tsui DWY, Grommes C, Viale A, Souweidane MM, Tabar V, Brennan CW, Reiner AS, Rosenblum M, Panageas KS, DeAngelis LM, Young RJ, Berger MF, Mellinghoff IK.

Nature. 2019 Jan;565(7741):654-658. doi: 10.1038/s41586-019-0882-3. Epub 2019 Jan 23.

15.

Tumor mutational load predicts survival after immunotherapy across multiple cancer types.

Samstein RM, Lee CH, Shoushtari AN, Hellmann MD, Shen R, Janjigian YY, Barron DA, Zehir A, Jordan EJ, Omuro A, Kaley TJ, Kendall SM, Motzer RJ, Hakimi AA, Voss MH, Russo P, Rosenberg J, Iyer G, Bochner BH, Bajorin DF, Al-Ahmadie HA, Chaft JE, Rudin CM, Riely GJ, Baxi S, Ho AL, Wong RJ, Pfister DG, Wolchok JD, Barker CA, Gutin PH, Brennan CW, Tabar V, Mellinghoff IK, DeAngelis LM, Ariyan CE, Lee N, Tap WD, Gounder MM, D'Angelo SP, Saltz L, Stadler ZK, Scher HI, Baselga J, Razavi P, Klebanoff CA, Yaeger R, Segal NH, Ku GY, DeMatteo RP, Ladanyi M, Rizvi NA, Berger MF, Riaz N, Solit DB, Chan TA, Morris LGT.

Nat Genet. 2019 Feb;51(2):202-206. doi: 10.1038/s41588-018-0312-8. Epub 2019 Jan 14.

PMID:
30643254
16.

Arterial thromboembolic events preceding the diagnosis of cancer in older persons.

Navi BB, Reiner AS, Kamel H, Iadecola C, Okin PM, Tagawa ST, Panageas KS, DeAngelis LM.

Blood. 2019 Feb 21;133(8):781-789. doi: 10.1182/blood-2018-06-860874. Epub 2018 Dec 21.

PMID:
30578253
17.

Phase 1b trial of an ibrutinib-based combination therapy in recurrent/refractory CNS lymphoma.

Grommes C, Tang SS, Wolfe J, Kaley TJ, Daras M, Pentsova EI, Piotrowski AF, Stone J, Lin A, Nolan CP, Manne M, Codega P, Campos C, Viale A, Thomas AA, Berger MF, Hatzoglou V, Reiner AS, Panageas KS, DeAngelis LM, Mellinghoff IK.

Blood. 2019 Jan 31;133(5):436-445. doi: 10.1182/blood-2018-09-875732. Epub 2018 Dec 19.

18.

Comprehensive approach to diagnosis and treatment of newly diagnosed primary CNS lymphoma.

Grommes C, Rubenstein JL, DeAngelis LM, Ferreri AJM, Batchelor TT.

Neuro Oncol. 2019 Feb 19;21(3):296-305. doi: 10.1093/neuonc/noy192.

PMID:
30418592
19.

BRAF Inhibition in BRAFV600-Mutant Gliomas: Results From the VE-BASKET Study.

Kaley T, Touat M, Subbiah V, Hollebecque A, Rodon J, Lockhart AC, Keedy V, Bielle F, Hofheinz RD, Joly F, Blay JY, Chau I, Puzanov I, Raje NS, Wolf J, DeAngelis LM, Makrutzki M, Riehl T, Pitcher B, Baselga J, Hyman DM.

J Clin Oncol. 2018 Oct 23:JCO2018789990. doi: 10.1200/JCO.2018.78.9990. [Epub ahead of print]

20.

Phase 1 study of pomalidomide and dexamethasone for relapsed/refractory primary CNS or vitreoretinal lymphoma.

Tun HW, Johnston PB, DeAngelis LM, Atherton PJ, Pederson LD, Koenig PA, Reeder CB, Omuro AMP, Schiff D, O'Neill B, Pulido J, Jaeckle KA, Grommes C, Witzig TE.

Blood. 2018 Nov 22;132(21):2240-2248. doi: 10.1182/blood-2018-02-835496. Epub 2018 Sep 27.

21.

Improving outcomes in primary CNS lymphoma.

Graham MS, DeAngelis LM.

Best Pract Res Clin Haematol. 2018 Sep;31(3):262-269. doi: 10.1016/j.beha.2018.07.006. Epub 2018 Jul 21. Review.

PMID:
30213395
22.

Letter to the Editor Regarding "National Trends for Reoperation in Older Patients with Glioblastoma".

Reiner AS, Goldman DA, Diamond EL, DeAngelis LM, Tabar V, Panageas KS.

World Neurosurg. 2018 Sep;117:466. doi: 10.1016/j.wneu.2018.04.156. No abstract available.

PMID:
30149428
23.

Ability of the Khorana score to predict recurrent thromboembolism in cancer patients with ischemic stroke.

Murthy SB, Cushman M, Bobrow D, Kamel H, Merkler AE, Elkind MSV, DeAngelis LM, Navi BB.

J Clin Neurosci. 2018 Nov;57:111-115. doi: 10.1016/j.jocn.2018.08.018. Epub 2018 Aug 23.

PMID:
30145085
24.

Marked Response of a Hypermutated ACTH-Secreting Pituitary Carcinoma to Ipilimumab and Nivolumab.

Lin AL, Jonsson P, Tabar V, Yang TJ, Cuaron J, Beal K, Cohen M, Postow M, Rosenblum M, Shia J, DeAngelis LM, Taylor BS, Young RJ, Geer EB.

J Clin Endocrinol Metab. 2018 Oct 1;103(10):3925-3930. doi: 10.1210/jc.2018-01347.

25.

Metastatic Complications of Cancer Involving the Central and Peripheral Nervous Systems.

Mendez JS, DeAngelis LM.

Neurol Clin. 2018 Aug;36(3):579-598. doi: 10.1016/j.ncl.2018.04.011. Epub 2018 Jun 15. Review.

26.

Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia.

Santomasso BD, Park JH, Salloum D, Riviere I, Flynn J, Mead E, Halton E, Wang X, Senechal B, Purdon T, Cross JR, Liu H, Vachha B, Chen X, DeAngelis LM, Li D, Bernal Y, Gonen M, Wendel HG, Sadelain M, Brentjens RJ.

Cancer Discov. 2018 Aug;8(8):958-971. doi: 10.1158/2159-8290.CD-17-1319. Epub 2018 Jun 7.

27.

The trials of neuro-oncology clinical research.

DeAngelis LM.

Neuro Oncol. 2018 Jul 5;20(8):1007-1008. doi: 10.1093/neuonc/noy076. No abstract available.

28.

Corticosteroid use endpoints in neuro-oncology: Response Assessment in Neuro-Oncology Working Group.

Arvold ND, Armstrong TS, Warren KE, Chang SM, DeAngelis LM, Blakeley J, Chamberlain MC, Dunbar E, Loong HH, Macdonald DR, Reardon DA, Vogelbaum MA, Yuan Y, Weller M, van den Bent M, Wen PY.

Neuro Oncol. 2018 Jun 18;20(7):897-906. doi: 10.1093/neuonc/noy056. Review.

29.

Metabolic Imaging of the Human Brain with Hyperpolarized 13C Pyruvate Demonstrates 13C Lactate Production in Brain Tumor Patients.

Miloushev VZ, Granlund KL, Boltyanskiy R, Lyashchenko SK, DeAngelis LM, Mellinghoff IK, Brennan CW, Tabar V, Yang TJ, Holodny AI, Sosa RE, Guo YW, Chen AP, Tropp J, Robb F, Keshari KR.

Cancer Res. 2018 Jul 15;78(14):3755-3760. doi: 10.1158/0008-5472.CAN-18-0221. Epub 2018 May 16.

30.

New diagnosis of cancer and the risk of subsequent cerebrovascular events.

Navi BB, Howard G, Howard VJ, Zhao H, Judd SE, Elkind MSV, Iadecola C, DeAngelis LM, Kamel H, Okin PM, Gilchrist S, Soliman EZ, Cushman M, Muntner P.

Neurology. 2018 Jun 5;90(23):e2025-e2033. doi: 10.1212/WNL.0000000000005636. Epub 2018 May 4.

31.

Multicenter Phase IB Trial of Carboxyamidotriazole Orotate and Temozolomide for Recurrent and Newly Diagnosed Glioblastoma and Other Anaplastic Gliomas.

Omuro A, Beal K, McNeill K, Young RJ, Thomas A, Lin X, Terziev R, Kaley TJ, DeAngelis LM, Daras M, Gavrilovic IT, Mellinghoff I, Diamond EL, McKeown A, Manne M, Caterfino A, Patel K, Bavisotto L, Gorman G, Lamson M, Gutin P, Tabar V, Chakravarty D, Chan TA, Brennan CW, Garrett-Mayer E, Karmali RA, Pentsova E.

J Clin Oncol. 2018 Jun 10;36(17):1702-1709. doi: 10.1200/JCO.2017.76.9992. Epub 2018 Apr 23.

32.

Distinctive Infectious Complications in Patients with Central Nervous System Lymphoma Undergoing Thiotepa, Busulfan, and Cyclophosphamide-conditioned Autologous Stem Cell Transplantation.

Scordo M, Morjaria SM, Littmann ER, Bhatia A, Chung HH, Maloy M, DeAngelis LM, Giralt SA, Taur Y, Sauter CS.

Biol Blood Marrow Transplant. 2018 Sep;24(9):1914-1919. doi: 10.1016/j.bbmt.2018.04.013. Epub 2018 Apr 18.

33.

Fertility preservation in primary brain tumor patients.

Stone JB, Kelvin JF, DeAngelis LM.

Neurooncol Pract. 2017 Mar;4(1):40-45. doi: 10.1093/nop/npw005. Epub 2016 Dec 9.

34.

Radiographic patterns of recurrence and pathologic correlation in malignant gliomas treated with bevacizumab.

Thomas A, Rosenblum M, Karimi S, DeAngelis LM, Omuro A, Kaley TJ.

CNS Oncol. 2018 Jan;7(1):7-13. doi: 10.2217/cns-2017-0025. Epub 2018 Feb 1.

35.

Reply: Arterial Thromboembolism in Non-Hodgkin Lymphoma, as the Presentation of Occult Cancer, and With Cancer Therapies.

Navi BB, Reiner AS, Kamel H, Iadecola C, Okin PM, Elkind MSV, Panageas KS, DeAngelis LM.

J Am Coll Cardiol. 2018 Jan 16;71(2):260-262. doi: 10.1016/j.jacc.2017.10.088. No abstract available.

36.

Enoxaparin vs Aspirin in Patients With Cancer and Ischemic Stroke: The TEACH Pilot Randomized Clinical Trial.

Navi BB, Marshall RS, Bobrow D, Singer S, Stone JB, DeSancho MT, DeAngelis LM.

JAMA Neurol. 2018 Mar 1;75(3):379-381. doi: 10.1001/jamaneurol.2017.4211. No abstract available.

37.

Overview of metastatic disease of the central nervous system.

Nolan C, Deangelis LM.

Handb Clin Neurol. 2018;149:3-23. doi: 10.1016/B978-0-12-811161-1.00001-3. Review.

PMID:
29307359
38.

Progressive multifocal leukoencephalopathy and hematologic malignancies: a single cancer center retrospective review.

Neil EC, DeAngelis LM.

Blood Adv. 2017 Oct 18;1(23):2041-2045. doi: 10.1182/bloodadvances.2017008201. eCollection 2017 Oct 24.

39.

A pilot study of neuropsychological functions, APOE and amyloid imaging in patients with gliomas.

Correa DD, Kryza-Lacombe M, Zhou X, Baser RE, Beattie BJ, Beiene Z, Humm J, DeAngelis LM, Orlow I, Weber W, Osborne J.

J Neurooncol. 2018 Feb;136(3):613-622. doi: 10.1007/s11060-017-2692-5. Epub 2017 Nov 22.

40.

The elderly left behind-changes in survival trends of primary central nervous system lymphoma over the past 4 decades.

Mendez JS, Ostrom QT, Gittleman H, Kruchko C, DeAngelis LM, Barnholtz-Sloan JS, Grommes C.

Neuro Oncol. 2018 Apr 9;20(5):687-694. doi: 10.1093/neuonc/nox187.

41.

Novel Considerations in the Approach to Glioblastoma.

Schaff LR, DeAngelis LM.

J Oncol Pract. 2017 Oct;13(10):639-640. doi: 10.1200/JOP.2017.027607. No abstract available.

42.

Long-term outcomes of adult medulloblastoma patients treated with radiotherapy.

De B, Beal K, De Braganca KC, Souweidane MM, Dunkel IJ, Khakoo Y, Gilheeney SW, DeAngelis LM, Menzel P, Patel SH, Wolden SL.

J Neurooncol. 2018 Jan;136(1):95-104. doi: 10.1007/s11060-017-2627-1. Epub 2017 Oct 10.

43.

Phase I study of sorafenib and tipifarnib for recurrent glioblastoma: NABTC 05-02.

Nghiemphu PL, Ebiana VA, Wen P, Gilbert M, Abrey LE, Lieberman F, DeAngelis LM, Robins HI, Yung WKA, Chang S, Drappatz J, Mehta MP, Levin VA, Aldape K, Dancey JE, Wright JJ, Prados M, Kuhn J, Cloughesy TF.

J Neurooncol. 2018 Jan;136(1):79-86. doi: 10.1007/s11060-017-2624-4. Epub 2017 Oct 7.

44.

Increased risk of arterial thromboembolism in older men with breast cancer.

Reiner AS, Navi BB, DeAngelis LM, Panageas KS.

Breast Cancer Res Treat. 2017 Dec;166(3):903-910. doi: 10.1007/s10549-017-4433-z. Epub 2017 Aug 23.

45.

Cerebrospinal fluid circulating tumor cells: a novel tool to diagnose leptomeningeal metastases from epithelial tumors.

Lin X, Fleisher M, Rosenblum M, Lin O, Boire A, Briggs S, Bensman Y, Hurtado B, Shagabayeva L, DeAngelis LM, Panageas KS, Omuro A, Pentsova EI.

Neuro Oncol. 2017 Sep 1;19(9):1248-1254. doi: 10.1093/neuonc/nox066.

46.

Risk of Arterial Thromboembolism in Patients With Cancer.

Navi BB, Reiner AS, Kamel H, Iadecola C, Okin PM, Elkind MSV, Panageas KS, DeAngelis LM.

J Am Coll Cardiol. 2017 Aug 22;70(8):926-938. doi: 10.1016/j.jacc.2017.06.047.

47.

Recurrent Thromboembolic Events after Ischemic Stroke in Patients with Primary Brain Tumors.

Parikh NS, Burch JE, Kamel H, DeAngelis LM, Navi BB.

J Stroke Cerebrovasc Dis. 2017 Oct;26(10):2396-2403. doi: 10.1016/j.jstrokecerebrovasdis.2017.05.031. Epub 2017 Jun 21.

48.

Prognostic awareness, prognostic communication, and cognitive function in patients with malignant glioma.

Diamond EL, Prigerson HG, Correa DC, Reiner A, Panageas K, Kryza-Lacombe M, Buthorn J, Neil EC, Miller AM, DeAngelis LM, Applebaum AJ.

Neuro Oncol. 2017 Oct 19;19(11):1532-1541. doi: 10.1093/neuonc/nox117.

49.

Primary CNS Lymphoma.

Grommes C, DeAngelis LM.

J Clin Oncol. 2017 Jul 20;35(21):2410-2418. doi: 10.1200/JCO.2017.72.7602. Epub 2017 Jun 22. Review.

50.

Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma.

Grommes C, Pastore A, Palaskas N, Tang SS, Campos C, Schartz D, Codega P, Nichol D, Clark O, Hsieh WY, Rohle D, Rosenblum M, Viale A, Tabar VS, Brennan CW, Gavrilovic IT, Kaley TJ, Nolan CP, Omuro A, Pentsova E, Thomas AA, Tsyvkin E, Noy A, Palomba ML, Hamlin P, Sauter CS, Moskowitz CH, Wolfe J, Dogan A, Won M, Glass J, Peak S, Lallana EC, Hatzoglou V, Reiner AS, Gutin PH, Huse JT, Panageas KS, Graeber TG, Schultz N, DeAngelis LM, Mellinghoff IK.

Cancer Discov. 2017 Sep;7(9):1018-1029. doi: 10.1158/2159-8290.CD-17-0613. Epub 2017 Jun 15.

Supplemental Content

Loading ...
Support Center